The study authors cautioned that immunological signatures cannot be predicted from tumor mutational burden or microenvironment analysis of a single biopsy alone.
The company is currently using the model, named EDGE, in its own personalized cancer vaccine work and in collaboration with outside immunotherapy developers.
The researchers will not only explore tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.
H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.
In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.
The partners will develop technology to predict the outcome of an NK-cell-based immunotherapy in patients with incurable locally advanced or metastatic solid tumors.
New data on Kadcyla and Tecentriq will help doctors further refine precision medicine options for breast cancer patients with unmet needs.
Researchers were able to identify 40 tumor-specific antigens within two mouse cancer cell lines and seven human primary tumors using this approach.
Company officials stressed the firm's drive to help connect industry and academia, and expand access to tools for precision medicine.
Using a mouse model of immunotherapy resistant disease, the researchers found that this program could be targeted by an inhibitor to improve response.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.